Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Common Equity (2022 - 2025)

CervoMed's Common Equity history spans 9 years, with the latest figure at $26.0 million for Q3 2025.

  • For Q3 2025, Common Equity fell 43.0% year-over-year to $26.0 million; the TTM value through Sep 2025 reached $26.0 million, down 43.0%, while the annual FY2024 figure was $39.2 million, 431.43% up from the prior year.
  • Common Equity for Q3 2025 was $26.0 million at CervoMed, down from $33.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $45.6 million in Q3 2024 and bottomed at -$35.1 million in Q2 2023.
  • The 4-year median for Common Equity is $8.5 million (2023), against an average of $4.4 million.
  • The largest annual shift saw Common Equity plummeted 210.22% in 2023 before it soared 405083.32% in 2025.
  • A 4-year view of Common Equity shows it stood at -$33.3 million in 2022, then surged by 122.16% to $7.4 million in 2023, then surged by 431.43% to $39.2 million in 2024, then tumbled by 33.65% to $26.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Common Equity are $26.0 million (Q3 2025), $33.4 million (Q2 2025), and $34.6 million (Q1 2025).